title: Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
abstract: Prostate cancer is the most prevalent urogenital malignancy. However, despite initial disease control using androgen deprivation, most of patients eventually develop progressive disease that is resistant to further hormone manipulation. For these patients with castration-resistant prostate cancer (CRPC), and particularly patients with metastatic disease, options have been limited, and prognosis is grim. However, as newer regimens and agents become available, higher rates of objective and biochemical response are being achieved, providing renewed hope for the management of these patients. With the aim of facilitating the treatment of these patients, the Spanish Oncology Genitourinary Group (SOGUG) has issued a series of the recommendations which have been collected in this review. Each recommendation is accompanied by the appropriate level of evidence and grade of recommendation on the basis of the characteristics of the data available.
authors.affiliation: Instituto Valenciano de Oncología (IVO), Valencia, Spain. macliment@fivo.org
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Climent
authors.forename: Josep María
authors.initials: JM
authors.lastname: Piulats
authors.forename: Alfredo
authors.initials: A
authors.lastname: Sánchez-Hernández
authors.forename: José Ángel
authors.initials: JÁ
authors.lastname: Arranz
authors.forename: Javier
authors.initials: J
authors.lastname: Cassinello
authors.forename: Jesús
authors.initials: J
authors.lastname: García-Donas
authors.forename: Aránzazu
authors.initials: A
authors.lastname: González del Alba
authors.forename: Luis
authors.initials: L
authors.lastname: León-Mateos
authors.forename: Begoña
authors.initials: B
authors.lastname: Mellado
authors.forename: María José
authors.initials: MJ
authors.lastname: Méndez-Vidal
authors.forename: Begoña
authors.initials: B
authors.lastname: Pérez-Valderrama
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone